HC Wainwright & Co. Maintains Buy on Belite Bio, Raises Price Target to $59
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Yi Chen maintains a 'Buy' rating on Belite Bio (NASDAQ:BLTE) and raises the price target from $55 to $59.
November 06, 2023 | 4:46 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Belite Bio's price target has been raised from $55 to $59 by HC Wainwright & Co., maintaining a 'Buy' rating.
The raised price target and maintained 'Buy' rating by HC Wainwright & Co. indicates a positive outlook for Belite Bio. This could potentially lead to an increase in the stock's price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100